How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

CL

NASDAQ:CLNN
Get a brief AI stock analysisSaves ~ 15 minutes of your time

CL

Clene Inc.NASDAQ CLNN Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is CLNN undervalued compared to its fair value?

The fair value of CLNN stock is hidden USD. Relative to the market price of 4.33 USD Clene Inc. is hidden.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah and currently employs 75 fu...[More about valuation]

Clene . Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.031 $B

Price:

4.33 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.086

FINANCIALS

Clene . financial for reporting period

Income Statement

0.0001 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0092 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.011 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.0001 B 100%
0.0001 B 78%
-0.0092 B -12647%
-0.011 B -15178%

Balance Sheet

0.045 B
0.0043 B

0.027 B

Financial Position Analysis

Assets

0.045 B
Current Assets
0.032 B
Total non-current assets
0.013 B

Total current liabilities
0.026 B
Total non-current liabilities
0.015 B

Cash Flow Statement

-0.0071 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0071 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Clene . fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-322 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-324 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-87 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is CLNN attractive for investment based on fundamental analysis?

CLNN stock rating is hidden. Clene . is a hidden by Eyestock methodology.

Get CLNN Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-7 835

Gross Margin:

78

CFO / Debt ratio:

hidden

Current ratio:

2.355

Debt / Equity ratio:

1.749

ROE:

-322

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

CLNN analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for CLNN to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Clene Inc. competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Clene Inc. dividends

CLNN dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About CLNN stock

About the company Clene Inc.

Market cap $B

0.031

Dividend yield

Shares outstanding

76.9292 B

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah and currently employs 75 full-time employees. The company went IPO on 2018-08-27. The firm is focused on the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure and neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is being evaluated in a Phase III registration trial in amyotrophic lateral sclerosis (ALS) and a Phase II trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). The firm has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.

CLNN profile

  • Ticker

    CLNN

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    27 August 2018

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    75

  • City

    Salt Lake City

  • Address

    6550 South Millrock Drive, Suite G50

  • Cusip

    185634102